Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Director | August 04, 2026 | August 06, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | January 02, 2026 | January 06, 2026 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Chief Bus. & Strat. Officer | March 06, 2018 | March 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 27,000 |
Reported balance
After 2026-08-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 27,000 · Balance 27,000 F1: The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date.
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Sierra Oncology, Inc.
Report date March 06, 2018 · Filed March 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2028-03-06 | Direct | 180,360 |
Reported balance
After 2018-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-06 · Grant · Acquired 180,360 · Balance 180,360 F1: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-03-21 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 73,731 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-11-30 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-26 · Disposition to issuer · Disposed 40,848 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 21:17 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001193125-26-338446 · ownership.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2036-08-03 F1 · derivative.exercise_date: The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001647664-26-000002 · form4-01062026_090103.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 00:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 1,403 | $9.43 | $13,230.29 |
DisclosureSEC source: 0001415889-25-018014 · form4-06242025_120613.xml · nonDerivative · entry 2 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 00:05 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 26,597 | $9.39 | $249,668.70 |
DisclosureSEC source: 0001415889-25-018014 · form4-06242025_120613.xml · nonDerivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,597 F1 · price: Represents the weighted average share price of an aggregate total of 26,597 shares purchased in the price range of $9.14 to $9.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000795 · form4-01062025_090153.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:26 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016916 · form4-06142024_080646.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 22:10 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 40,848 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005545 · form4-02272024_100213.xml · derivative · entry 2 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,848 shares Expires 2032-11-30 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 22:10 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 73,731 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005545 · form4-02272024_100213.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,731 shares Expires 2032-03-21 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated as of December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:58 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037398 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 17, 2022 Filed Jun 18, 2022 00:25 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 45,158 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001209191-22-038203 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,158 Underlying: Common Stock · 45,158 shares Expires 2032-06-16 F1 · derivative.exercise_date: (A) 11,958 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 22:53 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 33,250 | $0.00 Strike: $17.42 | $0.00 |
DisclosureSEC source: 0001209191-21-063926 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,250 Underlying: Common Stock · 33,250 shares Expires 2031-11-08 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest on each monthly anniversary of November 9, 2021. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 17:57 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 180,360 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-18-017785 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Chief Bus. & Strat. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,360 Underlying: Common Stock · 180,360 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 18:01 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | PurchaseCommon Stock | 30,000 | $1.43 | $42,900.00 |
DisclosureSEC source: 0001209191-17-019696 · doc4.xml · nonDerivative · entry 1 You Angie · CIK 0001647664 · Chief Bus. & Strat. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,252 Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-019361 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Chief Bus. & Strat. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:07 UTC | Sierra Oncology, Inc. DNAI · Entity 125698 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-16-144423 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Chief Bus. & Strat. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.